The Claim
Rezafungin received FDA approval in 2023, making it the most recently approved echinocandin antifungal agent indicated for the treatment of candidemia and invasive candidiasis in adult patients with limited therapeutic alternatives.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A new antifungal medicine called rezafungin was approved by the FDA in 2023 for treating serious yeast infections in adults who don't have many other treatment options.
See the scientific wording
The FDA approved rezafungin in 2023, making it the most recently approved echinocandin peptide antifungal for treating candidemia and invasive candidiasis in adults with limited treatment options.
What the research says
1 studyStudy: FDA-Approved Antibacterials and Echinocandins
The study confirms that the FDA approved an echinocandin peptide drug in 2023, which matches the claim about rezafungin. However, it's a general review and doesn't specifically name rezafungin or verify its exact use for treating candidemia and invasive candidiasis.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.